Oral Answers to Questions
Debate between Karl Turner and Gillian Keegan(2 years, 9 months ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Gillian Keegan
The National Institute for Health Research welcomes funding applications for research into any aspect of human health, including epilepsy, and we would welcome those pharmaceutical companies coming forward to partake in trials. The NIHR and the NHS will support a programme of two randomised control trials into epilepsy, which will compare medicines containing cannabidiol, and CBD plus tetrahydrocannabinol and a placebo. This is a pioneering area of research, and I am aware that NHS England and NIHR are working closely to get those trials started as soon as possible.
Karl Turner (Kingston upon Hull East) (Lab)
Randox Covid Contracts
Debate between Karl Turner and Gillian Keegan(3 years, 1 month ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Gillian Keegan
I will give way to hon. Members, but if they want to hear some of the facts, of which I have lots, I am happy to get on with my speech. I will give way to the hon. Member for Kingston upon Hull East (Karl Turner) on this occasion.
Karl Turner (Kingston upon Hull East) (Lab)
I am grateful to the Minister for giving way. She has been given a terribly tough gig, but she does not seem to be answering the point made a little earlier. Arco in Hull had existed for 135 years and had supplied the NHS with top-quality products since its very inception. It was blocked from the VIP lane—why?
Gillian Keegan
As I said, I would like to get on to answering some of these questions, so if Members will bear with me and let me get my speech out, I will have time to answer further interventions.
The context in which we were operating was the fear that we would run out of vital testing equipment, that we would not have the capacity to test people for covid and that, as a result, this deadly virus would continue to pass from person to person, overwhelm our national health service and cause untold devastation. It is the duty of any responsible Government to do all they can to prevent such a grim outcome, to save lives, to protect our key workers and to partner with as many people as are available with the experience and expertise to get things done. So we engaged with many thousands of businesses, large and small, from all over the country and all around the world, to set out what we needed and find out what they could do.
Randox has been globally recognised in the in vitro diagnostics industry for nearly 40 years. It is a British business with roots in Northern Ireland and a history of developing diagnostics solutions for hospitals, clinical settings and research labs. Even as early as March 2020, Randox had lab-based polymerase chain reaction testing capacity for covid-19. Against the fears that we would not have enough testing capacity, we worked with companies with existing diagnostic capability—that is just plain common sense.